Long-term anti-inflammatory drug use and Helicobacter pylori infection: a clinical, endoscopic and histological study.
BACKGROUND
Non-steroidal anti-inflammatory drugs (NSAIDs) and Helicobacter pylori are independent risk factors for gastroduodenal damage and peptic ulcer.


OBJECTIVE
To study the frequency and effect of H pylori infection on gastroduodenal mucosa in patients on long-term NSAID use.


METHODS
A total of 125 subjects were studied: 65 patients (Group 1) on NSAID therapy (> 6 months), 30 patients (Group 2) with arthritic disorders prior to starting NSAID therapy, and 30 healthy volunteers (Group 3). Dyspeptic symptoms were evaluated using a questionnaire. All patients underwent endoscopy and antral and duodenal biopsies were obtained to assess the extent of gastroduodenal damage and H pylori status.


RESULTS
H pylori infection was less frequent in Group 1 (37%) compared to Group 2 (57%, p = ns) and 3 (60%, p < 0.05). Among Group 1 patients, H pylori infection did not increase the risk of gastroduodenal damage (52% vs 45%) or ulceration (32% vs 27%). Group 1 patients with H pylori infection were more likely to be symptomatic (48% vs 27%) and have chronic active gastritis (76% vs 12%) and chronic active duodenitis (68% vs 5%). Gastric metaplasia was seen only in patients with H pylori infection, chronic active gastritis and duodenitis. Chemical gastritis was observed more commonly in Group 1 (34% vs 3%) compared to Group 2; its was not seen in Group 3. H pylori infection was less commonly observed in patients with chemical gastritis (8% vs 50%).


CONCLUSIONS
Patients on long-term NSAIDs are not at increased risk of H pylori infection. Presence H pylori infection is not associated with increased risk of gastroduodenal damage in these patients. H pylori infection correlated with presence of chronic active gastritis, and NSAID with presence of chemical gastritis.
Kulkarni
S G
SG
Department of Gastroenterology, BYL Nair Ch Hospital, Mumbai.
Parikh
S S
SS
Borges
N E
NE
Phadke
A Y
AY
Desai
S B
SB
Vora
I M
IM
Kalro
R H
RH
D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D004724:Endoscopy; D005753:Gastric Mucosa / Q000382:microbiology; D005756:Gastritis / Q000209:etiology; D016481:Helicobacter Infections / Q000150:complications*; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D010437:Peptic Ulcer / Q000209:etiology; D012307:Risk Factors
D000893:Anti-Inflammatory Agents